Hernexeos, zongertinib
Named-patient access overview. Hernexeos is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Hernexeos
Hernexeos (zongertinib) is manufactured by Boehringer Ingelheim and received US FDA accelerated approval in 2025 for adults with previously treated, HER2 (ERBB2)-mutant locally advanced or metastatic non-small cell lung cancer. It is an oral, irreversible HER2-selective tyrosine kinase inhibitor, designed to target HER2-mutant tumor signalling while sparing wild-type EGFR, which is the basis for the safety and efficacy profile observed in the Beamion LUNG-1 pivotal trial.
Hernexeos is taken by mouth once daily as set out in the prescribing information, with dose adjustments for diarrhea, transaminase elevation, interstitial lung disease, and other label-listed adverse events. HER2 mutation status on tissue or plasma must be confirmed before treatment. For international patients, Hernexeos may be coordinated through Named Patient Program or personal-import pathways with the destination country's regulator and the patient's treating oncologist handling the documentation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Hernexeos
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Hernexeos for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Hernexeos is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Hernexeos in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Hernexeos
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.